echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Amino Acids Research > Plum Creatures: Hi-Jie with amino acid business into the plum, waiting for the new strategy

    Plum Creatures: Hi-Jie with amino acid business into the plum, waiting for the new strategy

    • Last Update: 2020-06-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    's Foreign Investment Announcement: The Company intends to purchase 100% of the shares of Hi-Jie (Shenyang) Biotech Co., Ltd., Xijie (Siucheng) Biotech Co., Ltd., and Liaocheng Blue Sky Thermal Power Co., Ltd., which are established in China by issuing shares to Hijie and transferring old sharesAs the subject matter of the acquisition is a preliminary intention, the final target asset range has not yet been determined, the company applies for continued suspension of tradingWjU
    Introduction to the underlying company: Hi-Jie is a company established in accordance with Korean law and listed on the Korea Exchange, stock code: 097950.KSAccording to the results of the preliminary negotiations between the two sides, the scope of the share purchase includes all of Xijie's amino acid business in China, such as the Xijie Shenyang Plant, the Hijie Liaocheng Plant and the supporting Blue Sky Thermal Power PlantHijie has a strong strength in amino acid production, is expected to produce 400,000 tons of lysine annual output, sunine annual output of 50,000 tons, Xijie amino acid business total sales reached 10 billion yuanWjU
    The transaction led to major shareholder changes, the company will launch a new strategy: this transaction involves the transfer of the old shares of major shareholders and the issue of shares of Hijie China and Shijie China amino acid business is large, after the implementation of the transaction, Xijie will directly or indirectly become the largest shareholder of Meihua Bio, the original majority shareholder MrMeng Qingshan will become the company's second shareholderWe believe that Hi-Jie's acquisition of Meihua Bio makes it the world's largest amino acid producer, with an expected production capacity of more than 700,000 tons and susine production capacity of 200,000 tonsThe hi-jie group's positioning of the new plum company is not yet known, but the new company will have stronger industry pricing powerWjU
    Valuation and investment recommendations: According to the original plum production capacity launch plan, in 2016 Susine will increase production by 70,000 tons, sales are expected to rise; However, as the deal, Hija will become the largest shareholder, the next two years the company's strategy may change, earnings forecast uncertainty is greaterWjU 's Foreign Investment Announcement: The Company intends to purchase 100% of the shares of Hi-Jie(Shenyang) Biotech Co., Ltd., Xijie (Chicheng) Biotech Co., Ltd., and Liaocheng Blue Sky Thermal Power Co., Ltd., in the form of the issuance of shares issued to Hi-Jie and the transfer of old shares As the subject matter of the acquisition is a preliminary intention, the final target asset range has not yet been determined, the company applies for continued suspension of trading WjU
      Introduction to the underlying company: Hi-Jie is a company established in accordance with Korean law and listed on the Korea Exchange, stock code: 097950.KS According to the results of the preliminary negotiations between the two sides, the scope of the share purchase includes all of Xijie's amino acid business in China, such as the Xijie Shenyang Plant, the Hijie Liaocheng Plant and the supporting Blue Sky Thermal Power Plant Hijie has a strong strength in amino acid production, is expected to produce 400,000 tons of lysine annual output, sunine annual output of 50,000 tons, Xijie amino acid business total sales reached 10 billion yuan WjU
      The transaction led to major shareholder changes, the company will launch a new strategy: this transaction involves the transfer of the old shares of major shareholders and the issue of shares of Hijie China and Shijie China amino acid business is large, after the implementation of the transaction, Xijie will directly or indirectly become the largest shareholder of Meihua Bio, the original majority shareholder Mr Meng Qingshan will become the company's second shareholder We believe that Hi-Jie's acquisition of Meihua Bio makes it the world's largest amino acid producer, with an expected production capacity of more than 700,000 tons and susine production capacity of 200,000 tons The hi-jie group's positioning of the new plum company is not yet known, but the new company will have stronger industry pricing power WjU
      Valuation and investment recommendations: According to the original plum production capacity launch plan, in 2016 Susine will increase production by 70,000 tons, sales are expected to rise; However, as the deal, Hija will become the largest shareholder, the next two years the company's strategy may change, earnings forecast uncertainty is greater WjU
    Share it on feed
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.